Meeting
2022 ASCO Annual Meeting
Adverse events self-reported by patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with durvalumab (D) plus platinum-etoposide (EP) or EP in the CASPIAN study.
Authors
Mustafa Özgüroğlu
Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, Turkey
Mustafa Özgüroğlu , Jonathan W. Goldman , Yuanbin Chen , Marina Chiara Garassino , Nenad Medic , Helen Mann , Priti Chugh , Tapashi Dalvi , Luis G. Paz-Ares
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03043872
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8571)
DOI
10.1200/JCO.2022.40.16_suppl.8571
Abstract #
8571
Poster Bd #
198
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Dares: A phase II trial of durvalumab and ablative radiation in extensive stage small cell lung cancer.
First Author: Aditya Juloori
Poster
2023 ASCO Annual Meeting
Phase II study of durvalumab plus olaparib as maintenance therapy in extensive-stage small-cell lung cancer (TRIDENT): Preliminary efficacy and safety results.
First Author: Yan Huang
Poster
2023 ASCO Annual Meeting
The prognostic value of patient reported outcomes (PROs) and clinical/demographic variables in the CASPIAN study.
First Author: Apar Kishor Ganti